Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Sep 16, 2026
Joby Aviation (JOBY): Can It Reach $10 for a +60% Gain?

Joby Aviation (JOBY): Can It Reach $10 for a +60% Gain?

Key Takeaways

  • Joby Aviation (JOBY) recently traded near $6.13, well below its 52-week high of $19.98, putting a move to $10 roughly 60% away.
  • The $10 level sits close to the Wall Street consensus price target of about $10.68, making it a widely discussed and realistic objective.
  • Bullish drivers include FAA certification progress, a planned Dubai air taxi launch, a Toyota manufacturing partnership, and a strong cash position.
  • Key risks are heavy cash burn, share dilution from equity offerings, certification delays, and competition from rivals such as Archer Aviation (ACHR).
  • Major technical zones include support near the $6.10 low and resistance around the $7.40 50-day average before any test of $10.
  • The target is plausible but hinges on execution milestones rather than near-term momentum.

Why the $10 Level Stands Out

Joby Aviation, Inc., the electric vertical takeoff and landing (eVTOL) aircraft developer, has endured a punishing stretch. After peaking near $19.98 in late 2025, shares have fallen roughly 55% over the past year to the low single digits. Against that backdrop, $10 has become a psychological and analytical focal point: it is a clean round number that also happens to sit just beneath the consensus analyst price target of roughly $10.68.

For a stock trading near $6.13, reaching $10 would require a gain of about 60%. That is a meaningful but not implausible distance, which is precisely why the question of whether JOBY can reach $10 resonates with investors trying to gauge whether the recent decline is a buying opportunity or a warning sign. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position

Joby Aviation develops quiet, all-electric aircraft designed to carry a pilot and four passengers at speeds up to 200 miles per hour, with the goal of operating an aerial ridesharing service. The company is vertically integrated, designing, manufacturing, and eventually operating its own fleet.

Financially, Joby remains pre-profit. Trailing-twelve-month revenue was about $116 million against a net loss of roughly $878 million. However, the balance sheet provides a cushion, with about $2.26 billion in cash and a net cash position of roughly $1.52 billion after debt. That liquidity gives the company runway to pursue certification and early commercial operations, though it is being steadily consumed. From what I see, this cash position remains a key differentiator for now.

What Could Drive JOBY Toward $10

Several catalysts could support a recovery. First, Joby is advancing through the FAA type certification process, the regulatory gate that must open before commercial passenger service can begin in the United States. Any confirmation of progress toward final certification stages has historically moved the shares.

Second, the company holds exclusive air taxi rights in Dubai for six years under an agreement with the emirate's Roads and Transport Authority, and it has signaled plans for initial commercial operations in 2026. Real, visible passenger revenue from Dubai would mark a transition from a development-stage story to a commercial one.

Third, strategic partners add credibility. Toyota has invested close to $650 million and is collaborating on high-rate manufacturing, while Delta Air Lines (DAL) is a partner on premium airport transportation. Joby has also expanded production capacity with a large facility in Dayton, Ohio, positioning it to scale output once demand materializes.

What Could Prevent the Move

The most significant obstacle is cash consumption. Joby posted a full-year 2025 net loss of about $930 million and burned more than $500 million in operating cash, and it has raised capital through follow-on equity offerings, including a $750 million at-the-market program. Additional dilution would weigh on per-share value even as the business makes progress.

Timing risk is equally important. If FAA certification slips or the Dubai launch is delayed, the revenue that investors are pricing in could arrive later than expected. Competition also looms: Archer Aviation (ACHR) is targeting a similar U.S. launch window, and China's EHang already operates commercially, a reminder that early leadership does not guarantee dominance. High short interest of roughly 11% of shares outstanding and a beta near 2.7 further amplify volatility in both directions.

Analyst Price Targets

Wall Street's view is cautious but not dismissive. The consensus rating is a Hold, with an average twelve-month price target near $10.68, implying meaningful upside from current levels. Targets span a wide range, from a low around $6 to a high of $18, reflecting genuine disagreement about how quickly Joby can convert its technology into profitable operations. A $10 target sits squarely within that range, essentially matching the consensus and making it one of the more defensible objectives under discussion.

Technical Levels That Matter

From a technical standpoint, the stock's recent low near $6.10 represents the first line of support, and a breakdown below that level would undermine the recovery thesis. On the upside, the 50-day moving average near $7.40 and the 200-day moving average around $10.14 bracket the path toward $10. Notably, the 200-day average sits almost exactly at the target, meaning a move to $10 would also require reclaiming the stock's longer-term trend line — a meaningful test of whether the multi-month downtrend has reversed. I’m watching this closely as the averages converge.

Tracking Price Action with AI Signals

For traders seeking a more systematic approach to tracking Joby's price action, Tickeron's AI Daily Buy/Sell Signals offers an AI-driven alternative to manual chart analysis. The product continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-based analysis. Traders can use these signals to surface new opportunities, keep an eye on existing positions, and identify shifting market trends more efficiently than scanning charts by hand. As JOBY navigates a potentially pivotal period, having a consistent, data-driven signal framework can help investors stay ahead of changing momentum.

Final Assessment

Can Joby Aviation reach $10? The target is realistic but far from guaranteed. The strongest arguments in its favor are the balance sheet runway, high-profile partnerships with Toyota and Delta, and the prospect of initial commercial service in Dubai. The most serious counterweights are persistent cash burn, ongoing dilution, regulatory timing risk, and stiff competition.

Reaching $10 would likely require a sequence of confirmed milestones — progress toward FAA certification, a successful Dubai launch, and evidence that losses are narrowing — rather than a single headline. Investors should monitor certification updates, revenue growth, and cash-burn trends, while treating the $10 level as a threshold that depends fundamentally on execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JOBY

JOBY's RSI Oscillator slumps oversold zone

The RSI Indicator for JOBY moved into overbought territory on October 05, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for JOBY just turned positive on September 22, 2026. Looking at past instances where JOBY's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.

Following a +1.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where JOBY advanced for three days, in 206 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JOBY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for JOBY entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. JOBY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.446) is normal, around the industry mean (159.907). P/E Ratio (19.850) is within average values for comparable stocks, (14.484). JOBY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.572). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. JOBY's P/S Ratio (47.847) is very high in comparison to the industry average of (7.993).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JOBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.

Industry description

The Air Freight/Couriers industry operates air transportation and recurring delivery services. This includes companies offering same-day deliveries, scheduled delivery and logistical services. The proliferation of e-commerce/online retail with a growing emphasis on faster delivery has expanded opportunities for this industry, and induced more competition. United Parcel Service, Inc., FedEx Corporation and Expeditors International of Washington, Inc. are some of the major companies in this industry.

Market Cap

The average market capitalization across the Air Freight/Couriers Industry is 4.46B. The market cap for tickers in the group ranges from 2.17M to 58.27B. DPSGY holds the highest valuation in this group at 58.27B. The lowest valued company is PTNYF at 2.17M.

High and low price notable news

The average weekly price growth across all stocks in the Air Freight/Couriers Industry was -5%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -21%. PAC experienced the highest price growth at -2%, while SOAR experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Air Freight/Couriers Industry was -97%. For the same stocks of the Industry, the average monthly volume growth was -36% and the average quarterly volume growth was 56%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 67
Price Growth Rating: 70
SMR Rating: 66
Profit Risk Rating: 67
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
JOBY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AirFreightCouriers

Industry
N/A
Address
333 Encinal Street
Phone
+1 831 201-6700
Employees
2559
Web
https://www.jobyaviation.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.